Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
New England Journal of Medicine, 2020 BACKGROUND The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic ...
C. Cannon +14 more
semanticscholar +1 more source
Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes [PDF]
, 2010 OBJECTIVE This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing β-cells in subjects with new-onset type 1 diabetes.
Gottlieb, Peter A. +10 more
core +2 more sources
Genetics of type 2 diabetes [PDF]
Current Opinion in Clinical Nutrition and Metabolic Care, 2010 To provide an overview of the genetics of type 2 diabetes in the context of recent progress in the understanding of the genetic architecture of the disease and its applicability to the pathogenesis of the disease as well as efforts to individualize therapy in type 2 diabetes.
Adrian Vella, Galina Smushkin
openaire +3 more sources
Polymorphisms of the _ENPP1_ gene are not associated with type 2 diabetes or obesity in the Chinese Han population [PDF]
, 2008 *Objective:* Type 2 Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia and with a major feature of insulin resistance. Genetic association studies have suggested that _ENPP1_ might play a potential role in susceptibility to ...
Daizhan Zhou +11 more
core +1 more source
Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. [PDF]
, 2013 ObjectiveWe aimed to identify factors that are independently associated with the metabolic clearance rate of insulin (MCRI) and to examine the association of MCRI with incident type 2 diabetes in nondiabetic Hispanics and African Americans.Research ...
Anderson, Andrea M +10 more
core +2 more sources
HYPERTENSION AND DIABETES MELLITUS TYPE 2
Рациональная фармакотерапия в кардиологии, 2018 Aim. To study the effect of long-term combined antihypertensive therapy with lisinopril plus amlodipine on the parameters of central aortic pressure (CAD) and visceral obesity in patients with arterial hypertension (HT) combined with type 2 diabetes ...
M. E. Statsenko, M. V. Derevyanchenko
doaj +1 more source
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
New England Journal of Medicine, 2013 BACKGROUND The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
B. Scirica +17 more
semanticscholar +1 more source
Perceptions of a service redesign by adults living with type 2 diabetes [PDF]
, 2009 <b>Aim:</b> This article is a report of a study conducted to explore the perceptions of adults with type 2 diabetes towards the service redesign.
Brown, M. +4 more
core +1 more source
Early Maladjustment Schemas in Individuals with and without Type 2 Diabetes Mellitus [PDF]
, 2019 Objective. This study explored Early Maladjustment Schemas (EMSs) among individuals with and without type 2 diabetes mellitus and examined potential moderating roles for gender, level of education, and occupation. Methods.
Gholamrezaei, Simin +5 more
core +1 more source